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Abstract
Background: Ambulatory, community-based care for multi-drug resistant tuberculosis (MDR-TB) has been found to
be effective in multiple settings with high cure rates. However, little is known about patient preferences around
models of MDR-TB care. Médecins Sans Frontières (MSF) has delivered home-based MDR-TB treatment in the rural
Kitgum and Lamwo districts of northern Uganda since 2009 in collaboration with the Ministry of Health and the
National TB and Leprosy Programme. We conducted a qualitative study examining the experience of patients and
key stakeholders of home-based MDR-TB treatment.
Methods: We used semi-structured interviews and focus-group discussions to examine patients’ perceptions, views
and experiences of home-based treatment and care for MDR-TB versus their perceptions of care in hospital. We
identified how these perceptions interacted with those of their families and other stakeholders involved with TB.
Participants were selected purposively following a stakeholder analysis. Sample size was determined by data
saturation being reached within each identified homogenous category of respondents: health-care receiving,
health-care providing and key informant. Iterative data collection and analysis enabled adaptation of topic guides
and testing of emerging themes. The grounded theory method of analysis was applied, with data, codes and
categories being continually compared and refined.
Results: Several key themes emerged: the perceived preference and acceptability of home-based treatment and
care as a model of MDR-TB treatment by patients, family, community members and health-care workers; the fear of
transmission of other infections within hospital settings; and the identification of MDR-TB developing through poor
adherence to and inadequate treatment regimens for DS-TB.
Conclusions: Home-based treatment and care was acceptable to patients, families, communities and health-care
workers and was seen as preferable to hospital-based care by most respondents. Home-based care was perceived
as safe, conducive to recovery, facilitating psychosocial support and allowing more free time and earning potential
for patients and caretakers. These findings could contribute to development of an adaptation of treatment approach
strategy at national level.
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Background
Multi-drug resistant tuberculosis (MDR-TB) is defined
as disease caused by Mycobacterium tuberculosis that is
resistant to at least rifampicin and isoniazid. It can be
acquired primarily through direct infection or can de-
velop secondarily through inadequate treatment of drug-
susceptible TB (DS-TB). Its treatment is lengthy, com-
plex and can cause severe side effects. MDR-TB is an
emerging issue globally; in 2011, 630 000 of the 12 mil-
lion prevalent TB cases were MDR [1].
Historically, the model of MDR-TB treatment has been
hospital-based, with patients admitted to a central institu-
tion for the intensive phase of treatment or longer, which
usually means a minimum of 8 months [2]. Hospital-
based models of treatment are costly and often unfeasible
both for patients and health systems [3,4]. Only 16% of
the cases of MDR-TB estimated to exist among notified
TB patients were enrolled on treatment in 2010 [5].
Ambulatory, community-based care, whereby treat-
ment is administered on an outpatient basis from a local
community-based clinic often directly to patients in
their homes (home-based care), has been found to be ef-
fective in multiple settings with high cure rates [4,6,7].
Treatment at the community level is feasible and safe
and enables wider health influencing factors to be ad-
dressed including psychosocial support [8,9]. In addition,
community-based models of care are three to four times
cheaper than hospital-based approaches [3,10]. WHO
now recommends MDR-TB treatment models that are
primarily ambulatory [11,12]. However, little is known
about patient and staff acceptability of community-based
care in sub-Saharan Africa [13,14].
Uganda is classed as having a high burden of TB with
approximately 63 000 TB cases in 2011 (183/100 000
population) [1]. An estimated 1.4% of new and 12% of
previously treated TB cases are MDR, which means
there were around 1000 new cases of MDR TB in 2011
[1]. Nearly 90% of Uganda’s population live in rural areas
[15] and geographic access to health facilities is sub-
optimal. 72% of people were reported as living within
5km of the nearest health facility in 2005, with the
northern and eastern regions of Uganda having the
poorest access to health-care services [16]. Kitgum and
Lamwo are two adjacent rural districts in northern
Uganda which are currently comparatively stable but
historically have been subjected to conflict and displace-
ment, with devastating effects on the socio-economic
status of the population and health infrastructure.
Until recently there was no national MDR-TB treatment
programme in Uganda, with Médecins Sans Frontières
(MSF) being the sole treatment provider, delivering home-
based MDR-TB treatment in Kitgum and Lamwo districts
since 2009 in collaboration with the Ministry of Health
(MoH) and the National TB and Leprosy Programme.
The national DS-TB treatment provision has had associ-
ated drug shortages due to reasons including staff capacity
at local and district level to prepare quality and timely
anti-TB drug orders and at central level due to late prepar-
ation of drug orders and poor logistical support.
MDR-TB patients, under MSF’s home-based treatment
and care programme, receive individualised treatment
regimens according to drug-susceptibility testing (DST)
results and WHO guidelines, following the DOT ap-
proach as part of the Stop TB Strategy, as well as receiv-
ing education, psychosocial support and enablers such as
food rations. HIV co-infected patients in need of treat-
ment are offered integrated HIV care within MDR-TB
related activities. Initial treatment is delivered in a local
isolation unit (at Madi Opei Health Centre, Lamwo dis-
trict; or Kitgum Government Hospital) until the patient
is clinically stable and can be accommodated in a separ-
ate sleeping hut (‘tukul’) at home. The remainder of the
18-24 months of treatment is then delivered at home six
days per week, directly observed by health-care workers,
who are employed by MSF.
The MSF MDR-TB programme has achieved good re-
sults [17]. However, the acceptability and accessibility of
this model of care was not known. Although the Stop
TB Strategy highlights the importance of patient-centred
models of care [18] research on patients’ opinions and
preferences is scarce. We conducted a qualitative study
examining the experience of patients and key stake-
holders with the aim of determining the acceptability
and accessibility of the MDR-TB home-based treatment
and care programmes in Kitgum and Lamwo. We also
aimed to learn lessons from the programme implemen-
tation and obtain information to guide the development
and future implementation of this model of care.
Methods
We conducted a qualitative research study using semi-
structured interviews and focus-group discussions in
August and September 2011. We examined patients’
opinions, views and experiences of home-based treat-
ment and care for MDR-TB versus their assertions of
care in hospital. We also identified how these views
compared with those of their families and other stake-
holders involved with TB. These methods were chosen
due to the exploratory nature of the research question,
with interviews allowing an in-depth view to the opin-
ions and experiences of respondents, and focus-group
discussions showing group dynamics and general con-
sensus versus anomalies regarding this topic. The princi-
pal investigator did not occupy the dual role of clinician
and researcher, and therefore maintained a level of inde-
pendence to reduce study bias.
Participants were identified and selected purposively
following a stakeholder analysis, whereby all actors with
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a relationship to the topic (home-based treatment and
care or MDR-TB) were mapped, and their likely view to-
wards home-based treatment was rated from 1 to 5, with
1 being strongly negative view and 5 being strongly posi-
tive view. This mapping exercise also considered their
likely influence, interest in the issue and any assump-
tions made. A range of different actors were then invited
for interview through routine programme activities in
order to explore the diversity of opinions on this topic.
The principal investigator approached all identified par-
ticipants outlining the study and requesting voluntary
interview/focus-group discussion participation. Inter-
views and focus group discussions were audio-recorded
and lasted around 60 and 90 minutes, respectively. Sam-
ple size was determined by data saturation being reached
within each identified homogenous category of respon-
dents: health-care receiving, health-care providing and
key informants [19].
Interviews were based on the use of interview guides
with prompts, allowing a participant-led and flexible ap-
proach to data collection. Interviews were structured
around a core set of topics, including introductions, pa-
tient or family members’ experience of MDR-TB, as well
as diagnosis and treatment; and their views on recommen-
dations for future treatment provision. Conversation
around these topics was participant-led and naturally flo-
wed. Prompts and probes allowed particular topics to be
explored in more depth, for example on asking patients if
they spoke about having MDR-TB openly, it was then pos-
sible to explore their response to ascertain whether there
was a fear of negative response or stigma. This approach
allows for exploration of particular topics whilst still being
participant-led and not risking asking leading questions.
Topics used in health care provider and key informant in-
terviews were slightly different, including an examination
of the current system of treatment and care, acceptability
of home-based care, adherence and stigma. An interpreter
was used to translate questions and responses from Luo
to English and vice versa in several interviews and discus-
sions. A separate independent interpreter was used to re-
translate interview recordings where possible to ensure
validity of interpretations. Data were analysed throughout
the entire course of the research, in that from the moment
data were being generated the “thinking and theorising”
began [20]. This iterative process of data collection and
analysis enabled adaptation of topic guides and testing of
emerging themes. For example, following analysis of initial
patient interviews a code around patient adherence to
MDR-TB treatment emerged, which led to this being
added as a specific topic within interview guides in order
for this to be explored further. Data were managed ini-
tially through verbatim transcription of all recorded con-
versational interviews. Systematic analysis of transcripts
was conducted to identify codes, relevant themes, patterns
and concepts compatible to a deductive grounded theory
approach. A framework analysis was used to subdivide the
data as well as assign categories to ascertain the most sig-
nificant themes and patterns, with relationships between
constructs, as well as deviant cases, being identified [20,21].
Formal ethics approval was gained from the London
School of Hygiene and Tropical Medicine, MSF Ethics
Review Board and Ugandan Ethics Review Board prior
to the study commencing. Prior to interview commence-
ment and recording all participants voluntarily gave their
informed written consent. Confidentiality of respondents
was ensured through the use of pseudonyms and data
storage protection procedures. Feedback mechanisms
were used to ensure participants were aware of the find-
ings of the study and could choose to opt out.
Results
Participants
There were nine MDR and two mono-resistant patients
receiving treatment at the time of the study; previously
one MDR and three mono-resistant patients had com-
pleted treatment and been cured. All patients live in
small villages in remote rural settings and 63% of the
population in this region live below the poverty line [16].
Data saturation was reached in each respondent cat-
egory after 30 interviews: 12 health-care receiving, nine
health-care providing and nine key informant. Saturation
was defined as occurring when themes that emerged in
each respondent group were reiterated by different par-
ticipants; and when additional participant transcript ana-
lysis revealed no new themes. Respondents included
MDR-TB patients currently in the MSF home-based
treatment and care programme (n = 7), their family
members (5), health-care workers (6), village health team
members (3) and identified key informants from the
MoH (2) and non-governmental organisations (7). The
two MDR-TB patients who did not participate in the
study did so due to logistical reasons regarding time
availability and working hours. All other approached
participants voluntarily agreed to being interviewed.
Patients who agreed to participate were both male (4)
and female (3), their ages ranged from 15 to 70 years
and they were all from low socio-economic back-
grounds, the majority being illiterate. Responses were
analysed to account for gender and age differences; but
these demographic factors did not influence the themes
that emerged. A total of four focus group discussions
were conducted: one with village health team members
(6) and three with community members (10, 11 and nine
participants). Village health team members are govern-
mentally employed but in principle are volunteers, paid
mainly in incentives and a small stipend to perform a
role similar to community health workers. This focus
group included three males and three females. The
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community member focus groups were held with mem-
bers of a similar age and the same gender to minimise
the effects of power dynamics. Two focus groups were
held with groups of females (one with young females
and one with older) and one was held with young men.
Analysis
Several key themes emerged in relation to MDR-TB
treatment: the asserted preference for and acceptability
of home-based treatment and care as a model of MDR-
TB treatment by patients, family, community members
and health-care workers; the fear of nosocomial trans-
mission of other infections within hospital settings; and
the identification of MDR-TB developing through inad-
equate treatment regimens for DS-TB.
1. Perceived preference for home-based treatment and
care and high acceptability
‘I feel that getting treatment at home is better than
hospital.’ Patient 01
All twelve patients and family members interviewed
stated a preference for home-based care over hospital-
based care, with some mentioning that this was condi-
tional to the drug supply being constant and reliable.
Acceptability of this model of care was high: home-
based treatment and care was accepted by all health-care
receiving respondents; the two district MoH respon-
dents; all three village health team respondents; and five
of the six health-care worker respondents. The one
health-care worker respondent who was ambivalent was
a nurse who feared secondary transmission within the
community. The majority of community members who
participated in focus group discussions stated a prefer-
ence for home-based treatment and none mentioned a
lack of acceptance of having patients in their communi-
ties being treated for MDR-TB at home. All members of
village health teams interviewed said they would be will-
ing to deliver MDR-TB treatment at home.
Home was perceived as an environment which:
 Is more conducive to recovery than hospital:
‘I saw during the home-based care period patients get
a lot of improvement in home than in the hospital.’
Family member 05
‘I think from home someone recovers much faster than
when hospitalised.’ Health-care worker 03
 Enables more psychosocial support due to the
closeness of family and friends and perceived
connectedness in comparison with feelings of
isolation and loneliness associated with hospital
admission:
‘Having people coming home, chatting with you, it is
nice and encourages you to take the drugs.’ Patient 02
 Provides free time for both the caretaker and the
patient to conduct other activities such as
performing small jobs and having social interactions.
Respondents also mentioned socioeconomic barriers
to accessing treatment in hospital, including distance, af-
fordability, transport costs, living costs while in hospital
and distance from home creating indirect costs through
lack of ability for the patient or caretaker to work. These
barriers were seen as being particularly prohibitive of
treatment access if the hospital were to be a centralised
institution such as Mulago hospital in Kampala (the pro-
posed provisory institute for treatment nationally), with
the socio-economic factors mentioned above as well as
language barriers making the vast majority of patients
and family members feel they would be unable to receive
treatment from this location.
‘If I was in the hospital in Kampala the cost for
transport is very expensive and someone must come to
see you and stay for 1 month maybe, then they cannot
do other things in this time and it would be very
costly.’ Patient 02
‘Because the patient comes from a poor family, he
cannot raise the money to go to Mulago [National
Referral Hospital in Kampala]’ MoH 02
Home-based treatment and care was therefore seen to
be more accessible to patients and their family members,
as well as more acceptable to both health-care receiving
and health-care providing respondents.
2. Fears of transmission of MDR-TB and other infections
No patient or family respondents mentioned fears or as-
sociation of treatment at home with heightened risk of
secondary transmission of MDR-TB. However, three
health-care workers and several key informant respon-
dents mentioned fears of potential MDR-TB transmission
with home-based care and highlighted the need for isola-
tion of patients during the initial phase of treatment, ei-
ther in a special tukul at home or in a local isolation ward.
Respondents mentioned perceiving hospital as being an
environment that poses greater risk for catching other in-
fections via nosocomial transmission and the majority of
respondents felt the home environment would be more
protective of patients’ health in this regard.
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Community members in general were positive about
the idea of patients being treated at home: the majority
of women and young women in two focus groups
thought home was the best place for people with MDR-
TB to be treated; and nearly half the young men in an-
other focus group preferred home - the other half were
either unsure or said they would prefer hospital due to
perceptions that treatment would be more likely to be
delivered on time. No participants of these community
focus group discussions mentioned a fear of MDR-TB
transmission to themselves associated with patients be-
ing treated at home within the community.
Several respondents mentioned the existence of stigma
towards MDR-TB patients, in each case linked to the as-
sociation of MDR-TB with HIV. The stigma perceived or
enacted was not due to the MDR-TB itself but rather its
association with HIV, and was said to usually come in
the form of rumours. Participants felt that this was due
to health promotion messages that state that HIV and
TB go hand in hand and therefore someone with TB is
assumed to be HIV positive. In addition, symptoms were
perceived as being similar for both conditions.
‘Actually because when you see the signs and
symptoms of HIV compared with that of tuberculosis,
normally they are similar… loss of weight, the
appearance of the face, the hair, moves similar to that
of HIV.’ Focus group discussion 04 – young males
The vast majority of respondents who observed stigma
either felt or had seen this being overcome by commu-
nity sensitisation:
‘After the sensitisation within here there is now
nothing, people are living normal lives, they are
supporting us and others with ideas, we can chat
freely.’ Family member 01
3. Inadequate treatment of DS-TB
Nine of the 12 health-care receiving respondents felt
they could identify the origin of patients’ MDR-TB. Of
these nine, most associated MDR-TB development with
interruptions in nationally provided DS-TB treatment.
Reasons cited included a lack of drug availability (with pa-
tients mentioning going to health clinics for drug refills
and finding there were no drugs), lack of staff availability
for dispensing refills and procurement of expired drugs:
‘I used to go to the hospital and there would be no
drugs’ Patient 01
‘I was taking expired drugs for a very good period’
Patient 06
Several health-care workers echoed these views on
treatment availability for DS-TB, mentioning lack of
consistency in drug supplies, low drug stocks and pe-
riods when there were no drugs available.
Some health-care workers and key informants associ-
ated MDR development with the adherence of DS-TB
patients as well as treatment shortages:
‘It is an issue of adherence, they stop start stop start if
they feel better.’ Key informant 02
Respondents’ opinions on MDR-TB development in
this context highlight potential issues in need of atten-
tion, including patient education to improve adherence
to DS-TB treatment and improvements in drug supply.
Discussion
The results show that home-based treatment and care
was acceptable to patients, families, communities and
health-care workers and was seen as preferable to
hospital-based care by most respondents in all groups,
including by all interviewed patients and family mem-
bers. Home-based care was also viewed as safe, condu-
cive to recovery, facilitating psychosocial support and
allowing more free time and earning potential for pa-
tients and caretakers. While some health-care workers
were concerned about infection transmission risks with
home-based care, patients were instead concerned about
hospital-acquired infections. In addition to MDR-TB
treatment, MSF provided information on MDR-TB and
infection control to the patient and their extended
household, including education around modes of trans-
mission. Patients were isolated in a separate Tukul (hut)
within the home during the initial phase of treatment,
while they were sputum positive, the logistics of which
were supported by MSF. Home visits were conducted by
MSF medical staff and a counsellor, who paid attention to
the patient’s experience as well as perceptions of the fam-
ily. These factors would have influenced the results with
regards to assertions around MDR-TB transmission.
Most participants identified MDR-TB as having devel-
oped from DS-TB treatment interruptions. That certain
health-care workers and key informants also associated
MDR development with DS-TB patient adherence is a
crucial point which warrants further investigation into
the treatment for DS-TB and specific action targeting
adherence to this treatment.
The need for a treatment strategy in Uganda, which
rapidly and adequately treats MDR-TB and HIV has
been highlighted elsewhere, with one study finding the
retreatment approach to TB to be unsatisfactory [22].
Our study is the first to assess the acceptability of a
model of home-based treatment and care for MDR-TB
for patients and staff. However, this is complemented by
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several studies examining community-based models of
treatment for DS-TB and MDR-TB in multiple settings,
including Uganda. These show community or home-
based treatment to be effective, feasible and safe [6-8] as
well as supportive of adherence [23].
Qualitative research exploring patients’ responses to
various models of MDR-TB treatment is lacking, and
thus our study provides an insight into a patient-centred
approach to assessing this model of treatment and care.
In qualitative research examining the DOTS approach
for DS-TB, support and treatment delivery that were
patient-centred, rather than enforced via inspectorial ob-
servation, resulted in higher treatment uptake and adher-
ence [24] as did the addition of social and psychological
support [23]. Other research has highlighted the need for
treatment that goes beyond provision of anti-TB drugs to
include care and support delivered via ground-up models
[25] and a focus on patient contacts as well as patients
themselves [26]. These findings are in line with Compo-
nent 5 of the Stop TB Strategy, outlining the need for pa-
tient and community involvement in TB care to achieve
sustainable and effective TB initiatives [18].
Health and treatment outcomes have been shown to
be influenced by the psychosocial and economic aspects
of treatment and care for MDR-TB [9]. In our study, re-
spondents described factors relating to health and treat-
ment outcomes as being enhanced through home-based
care. Socioeconomic access barriers were mentioned in
association with hospital-based but not home-based
care. A similar finding was noted in qualitative research
examining the DOTS approach for DS-TB, with barriers
described including patients not being able to undertake
treatment due to cost of transport to services and loss of
earnings through inability to work [24]. In our study, re-
spondents noted that home-based care allowed psycho-
logical support from family members and social contact
with friends and community members. They also de-
scribed close relationships with MSF staff including
counsellors and the health-care workers who directly ob-
served treatment. These factors were seen to facilitate
the treatment process, giving strength of mind and posi-
tivity to patients and encouraging them with adherence.
Respondents did not mention any patients experiencing
difficulties with adherence, however this topic was not
examined specifically and thus conclusions cannot be
drawn. All MDR-TB patients interviewed mentioned the
importance of being able to have free time for other
activities.
Our study showed that some health-care workers were
concerned about the risk of transmission of MDR-TB if
patients were treated at home, while conversely patients
were concerned about the risk of catching other infections
in hospital. The perceptions of the patients reflect findings
that there are fewer opportunities for transmission of
other infections with home-based MDR-TB treatment and
care [4]. Further research is required to examine second-
ary transmission of MDR-TB in both hospital and com-
munity treatment models. Our results demonstrated that
fears of MDR-TB infections lay with health-care profes-
sionals rather than with health-care receivers, which war-
rants further investigation into how such fears might
guide health-care worker practice and whether these fears
are warranted. This finding also calls for programmatic at-
tention to ensure adequate training of staff on the risks of
nosocomial transmission and transmission prevention
measures used in home-based treatment settings.
Respondents outlined the existence of weaknesses
within current national DS-TB health services including
the provision of expired drugs, lack of drug availability
and drug stock outs, lack of staff availability for refill dis-
pensing, and lack of support and information to encour-
age patients to adhere to treatment. There is need for
adequate treatment provision for DS-TB in order to pre-
vent the selection of naturally occurring mutations that
cause MDR-TB to develop [27]. Our results highlighted
the importance of a strengthened drug supply line to
villages, since the role of supply interruptions for TB
medication in development of MDR resistance was ac-
knowledged by both patients and medical staff. The
negative effects of drug stock outs have been shown in
HIV, though there is a dearth of research in this area for
TB [28]. To address the issue of interrupted drug supply
lines, MSF has trained suppliers and relevant Ministry of
Health staff in medical supply ordering processes.
In July 2012, Uganda’s Ministry of Health began rolling
out its first national treatment programme for MDR-TB,
which aims to treat around 250 already confirmed cases.
The proposed treatment strategy involves initial hospi-
talisation followed by ambulatory care with patients be-
ing monitored by regional health centres and treatment
delivered at the community level by village health teams.
Our findings on patients’ experiences of home-based
care could be used to contribute to adaptation of treat-
ment approach strategy at national level.
Limitations
Our study design was explorative and the findings are
not generaliseable to all contexts and settings. However,
our work highlights issues likely to be relevant to many,
particularly those with a similarly high proportion of rur-
ally situated patients with low socioeconomic status; and
is supported by findings that ambulatory or community-
based care is feasible and effective. Analysis of participant
accounts is interpretative and involves the “positioned”
researcher [29]. Reflexivity about the influence of the re-
searcher on shaping the data was ensured through aware-
ness of potential researcher biases and analysing verbatim
transcriptions word-for-word to avoid interpretation of
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meaning by the researcher. Coding and emergent themes
were also checked by a second researcher to minimise po-
tential bias. The principal investigator is a young white
British female; the power dynamic of researcher and par-
ticipant has been acknowledged throughout data collec-
tion and analysis and has been minimised by the fact that
the principal investigator had no responsibility for
programme management or patient care and was an out-
sider to routine programme activities.
The design of this study precluded collection of data
on resistance patterns and increase in vulnerability to
the development of resistance. While it demonstrates
that fears of barriers to treatment created by stigma and
community rejection are unfounded, this present proof
of acceptability to patients and communities is not in it-
self adequate to demonstrate that home-based care for
MDR-TB is equally effective or superior to hospital-
based care as we have not assessed the effect of the ex-
tension of current supply lines for MDR-TB medications
that would be needed in an expanded home-based care
model.
Conclusion
In a rural setting in Uganda, home-based treatment and
care for MDR-TB was found to be preferred by patients
and staff to hospital-based care for three main reasons:
it was seen as being more conducive to patient recovery,
it enabled enhanced psychosocial support and it allowed
more free time for patients and caretakers to conduct
other activities. Patients and staff viewed home-based
treatment and care to be patient-centred, accessible, ac-
ceptable and feasible in this setting. Assertions on noso-
comial transmission and drug supply interruptions
highlight the need for improved training on infection
control for health-care workers.
It is essential not to overlook the importance of reli-
able drug supply lines and buffer stock management for
DS and MDR-TB programmes, with contingency plan-
ning in case of failure of supply lines. Studies to research
this issue are currently lacking but are urgently needed
to inform programming decisions and donor choices.
RATS guidelines
This study adheres to the RATS Guidelines on qualita-
tive research.
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